Aman M. Patel

Aman M. Patel

Auto-generated profile, based on publicly available information

Aman M. Patel

Rutgers New Jersey Medical School Newark New Jersey USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MAMartin P Alphonse
Martin P Alphonse
JRJessica H. Rubens
Jessica H. Rubens
RORoger V. Ortines
Roger V. Ortines
NONicholas A. Orlando
Nicholas A. Orlando
APAman M. Patel
Aman M. Patel
LMLloyd S. Miller
Lloyd S. Miller
A pan-caspase inhibitor, Q-VD-OPH, has therapeutic efficacy against preclinical methicillin-resistant Staphylococcus aureus skin infection.

6 June 2023 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
APAman M. Patel
Aman M. Patel
SVSudeepti Vedula
Sudeepti Vedula
AHAfash Haleem
Afash Haleem
HCHassaam S. Choudhry
Hassaam S. Choudhry
CTChristopher C. Tseng
Christopher C. Tseng
RPRichard Chan Woo Park
Richard Chan Woo Park

5 December 2022 in World Neurosurgery
Verified
Journal Article
Closed access
APAlejandro Pando
Alejandro Pando
APAman M. Patel
Aman M. Patel
HCHannaan S. Choudhry
Hannaan S. Choudhry
JEJean Anderson Eloy
Jean Anderson Eloy
IGIra M. Goldstein
Ira M. Goldstein
JLJames K. Liu
James K. Liu

14 March 2024 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
APAman M. Patel
Aman M. Patel
AHAfash Haleem
Afash Haleem
HCHassaam S. Choudhry
Hassaam S. Choudhry
RPRoman Povolotskiy
Roman Povolotskiy
DRDylan F. Roden
Dylan F. Roden
Objective: To investigate adjuvant therapy indications, utilization, and associated survival disparities in major salivary gland cancer (MSGC).Study Design: Retrospective cohort study.Setting: The 2006 to 2017 National Cancer Database.Methods: Patients with surgically resected MSGC were included (N = 11,398). pT3‐4 classification, pN2‐3 classification, lymphovascular invasion, pathologic extranodal extension (pENE), and positive surgical margin (PSM) were considered indications for adjuvant radiotherapy (aRT). pENE and PSM were considered possible indications for adjuvant chemotherapy. Multivariable logistic and Cox regression models were implemented.Results: Among 6694 patients with 1 indication for aRT, 1906 (28.5%) received no further treatment and missed aRT. Age, race, comorbidity status, facility type, and distance to reporting facility were associated with missed aRT (P < .025). Among 4003 patients with ≥1 possible indication for adjuvant chemoradiotherapy (aCRT), 914 (22.8%) received aCRT. Patients with pENE only (38.5%) and both pENE and PSM (44.0%) received aCRT more frequently than those with PSM only (17.0%) (P < .001). Academic facility was associated with aCRT utilization (P < .05). aCRT utilization increased between 2006 and 2017 in both academic (14.8% vs 23.9%) and nonacademic (8.8% vs 13.5%) facilities (P < .05). Among 2691 patients with ≥1 indication for aRT alone, missed aRT portended poorer OS (hazard ratio [HR]: 1.61, 95% confidence interval [CI]: 1.28‐2.03, P < .001). Among 4003 patients with ≥1 possible indication for aCRT, aRT alone (HR: 1.02, 95% CI: 0.89‐1.18, P = .780) and aCRT were associated with similar OS.Conclusion: Missed aRT in MSGC occurs frequently and portends poorer OS. Further studies clarifying indications for aCRT are required.

30 December 2022 in Head & Neck
Verified
Journal Article
Closed access
APAman M. Patel
Aman M. Patel
HCHannaan S. Choudhry
Hannaan S. Choudhry
ADAmar D. Desai
Amar D. Desai
VSVraj P. Shah
Vraj P. Shah
PPPrayag Patel
Prayag Patel
CFChristina H. Fang
Christina H. Fang

1 March 2024 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
APAman M. Patel
Aman M. Patel
AHAfash Haleem
Afash Haleem
HCHassaam S. Choudhry
Hassaam S. Choudhry
JBJason A. Brant
Jason A. Brant
RBRobert M. Brody
Robert M. Brody
RCRyan M. Carey
Ryan M. Carey
Objective: To compare surgical and nonsurgical definitive treatment in cT4b major salivary gland cancer (MSGC).Study Design: Retrospective cohort study.Setting: The 2004 to 2019 National Cancer Database.Methods: The NCDB was queried for patients with cT4b MSGC (N = 976). Patients undergoing definitive treatment with (1) surgical resection + adjuvant therapy, (2) radiotherapy (RT) alone, or (3) chemoradiotherapy (CRT) were included in Kaplan‐Meier and Cox survival analyses.Results: Of 219 patients undergoing definitive treatment, 148 (67.6%) underwent surgical resection + adjuvant therapy and 71 (32.4%) underwent RT or CRT. There were no documented mortalities within 90 days of surgical resection. Tumor diameter and nodal metastasis were associated with decreased odds of undergoing definitive treatment (P < 0.025). Patients with positive surgical margins (PSM) had higher 5‐year overall survival (OS) than those undergoing definitive RT or CRT (48.5% vs 30.1%, P = 0.018) and similar 5‐year OS as those with negative margins (48.5% vs 54.0%, P = 0.205). Surgical resection + adjuvant therapy (adjusted hazard ratio: 0.55, 95% confidence interval [CI]: 0.37‐0.84) was associated with higher OS than definitive RT or CRT (P < 0.025). A separate cohort of 961 patients with cT4a tumors undergoing surgical resection + adjuvant therapy was created; cT4a and cT4b (hazard ratio: 1.02, 95% CI: 0.80‐1.29, P = 0.896) tumors had similar OS.Conclusion: A minority of patients with cT4b MSGC undergo definitive treatment. Surgical resection + adjuvant therapy was safe and associated with higher OS than definitive RT or CRT, despite high rate of PSM. In the absence of clinical trial data, appropriately selected patients with cT4b MSGC may benefit from surgical resection.